Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Up 3.7%

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) was up 3.7% during trading on Monday . The stock traded as high as 1.55 and last traded at 1.53. Approximately 4,342,382 shares were traded during mid-day trading, an increase of 18% from the average daily volume of 3,688,101 shares. The stock had previously closed at 1.47.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on CATX shares. B. Riley upped their price target on Perspective Therapeutics from $1.20 to $1.70 and gave the company a “buy” rating in a research report on Tuesday, April 9th. Oppenheimer reaffirmed an “outperform” rating and set a $1.50 target price (up previously from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st.

Perspective Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.07 and a current ratio of 1.07.

Insider Transactions at Perspective Therapeutics

In other news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was purchased at an average cost of 0.95 per share, for a total transaction of 57,409,487.05. Following the acquisition, the insider now owns 116,773,394 shares of the company’s stock, valued at 110,934,724.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, insider Markus Puhlmann bought 280,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 24th. The stock was bought at an average cost of 0.50 per share, for a total transaction of 140,000.00. Following the acquisition, the insider now directly owns 1,375,425 shares of the company’s stock, valued at approximately 687,712.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of Perspective Therapeutics stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average price of 0.95 per share, for a total transaction of 57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares in the company, valued at 110,934,724.30. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 60,758,439 shares of company stock valued at $57,576,503. Insiders own 5.72% of the company’s stock.

Institutional Trading of Perspective Therapeutics

A number of institutional investors have recently made changes to their positions in CATX. Vanguard Group Inc. boosted its holdings in shares of Perspective Therapeutics by 3.1% during the fourth quarter. Vanguard Group Inc. now owns 13,213,750 shares of the company’s stock worth $5,312,000 after purchasing an additional 395,124 shares during the period. Taylor & Morgan Wealth Management LLC grew its position in shares of Perspective Therapeutics by 8.7% in the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock worth $251,000 after buying an additional 50,000 shares during the last quarter. Creative Planning purchased a new position in shares of Perspective Therapeutics during the third quarter valued at approximately $35,000. HighTower Advisors LLC bought a new position in shares of Perspective Therapeutics during the third quarter valued at approximately $314,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Perspective Therapeutics in the third quarter worth $32,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.